Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23778486 | 0.84 | AKT1 (0.45) | AKT1RAB9ACNR1CNR2DRD2 | |
| SCHEMBL23778929 | 0.82 | RAB9A (0.48) | AKT1RAB9ACNR1CNR2NAMPT | |
| SCHEMBL24822317 | 0.80 | AKT1 (0.43) | AKT1CNR1CNR2DRD2PDE2A | |
| SCHEMBL89859 | 0.79 | AKT1 (0.42) | AKT1RAB9ACNR1CNR2DRD2 | |
| SCHEMBL2713905 | 0.78 | AKT1 (0.42) | AKT1RAB9ACNR1CNR2DRD2 | |
| SCHEMBL18292853 | 0.78 | VNN1 (0.40) | AKT1 | |
| SCHEMBL2554955 | 0.78 | AKT1 (0.47) | AKT1RAB9ACNR1CNR2AKT2 | |
| SCHEMBL1669707 | 0.77 | AKT1 (0.41) | AKT1RAB9ACNR1CNR2PDE2A | |
| SCHEMBL18551335 | 0.77 | MIF (0.46) | AKT1CNR1CNR2DRD2PDE2A | |
| SCHEMBL22438589 | 0.76 | AKT1 (0.41) | AKT1CNR1CNR2DRD2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722688-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO (US) | 2013-08-01 | — | — | US | disclosed |
| CN-102906080-A | Compounds for the treatment of hepatitis C | BRISTOL MYERS SQUIBB CO | 2013-01-30 | — | — | CN | disclosed |
| EP-2545042-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-13 | — | — | US | disclosed |
| US-8309558-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| US-8148382-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110256099-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-20 | — | — | US | disclosed |
| WO-2011112191-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| US-7994171-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100249094-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249094-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | AKT1 2182/4885RAB9A 2224/4885CNR1 1711/4885 |
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | AKT1 2182/4885RAB9A 2224/4885CNR1 1711/4885 |
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | AKT1 2182/4885RAB9A 2224/4885CNR1 1711/4885 |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, SLC10A1 | AKT1 2182/4885RAB9A 2224/4885CNR1 1711/4885 |
| US-20110256099-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | AKT1 2182/4885RAB9A 2224/4885CNR1 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.